Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Kami Maddocks, MD, Erin K Hertlein, PhD, Joseph M. Flynn, DO, MPH, Leslie A Andritsos, MD, Amy J. Wagner, Timothy L. Chen, Mitch A. Phelps, PhD, Michael R. Grever, MD, Amy J. Johnson, PhD, John C. Byrd, MD, Jeffrey A. Jones, MD, MPH

Blood (2012) 120 (21): 1800.

https://doi.org/10.1182/blood.V120.21.1800.1800

Published: 2012

Journal Articles

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

Emilia Mahoney, David M. Lucas, Sneha V. Gupta, Amy J. Wagner, Sarah E. M. Herman, Lisa L. Smith, Yuh-Ying Yeh, Leslie Andritsos, Jeffrey A. Jones, Joseph M. Flynn, Kristie A. Blum, Xiaoli Zhang, Amy Lehman, Hui Kong, Metin Gurcan, Michael R. Grever, Amy J. Johnson, John C. Byrd

Blood (2012) 120 (6): 1262–1273.

https://doi.org/10.1182/blood-2011-12-400184

Published: 2012

Includes: Supplemental data

Journal Articles

Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines

Amy J. Johnson, PhD, Lisa L. Smith, Amy J. Wagner, Joshua Hessler, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Xiaoli Zhang, Amy Lehman, David Jarjoura, Michael R. Grever, M.D., Rajat Bannerji, MD, PHD, John C. Byrd, MD

Blood (2010) 116 (21): 971.

https://doi.org/10.1182/blood.V116.21.971.971

Published: 2010

Journal Articles

Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol

Emilia Mahoney, MD, PhD, Amy J. Johnson, PhD, Amy J. Wagner, Joshua Hessler, Sneha V. Gupta, Sarah E.M. Herman, Leslie Andritsos, MD, Jeffrey A. Jones, MD, MPH, Joseph M. Flynn, DO, MPH, David M. Lucas, PhD, Michael R. Grever, M.D., John C. Byrd, MD

Blood (2010) 116 (21): 691.

https://doi.org/10.1182/blood.V116.21.691.691

Published: 2010

Journal Articles

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Sarah E. M. Herman, Amber L. Gordon, Amy J. Wagner, Nyla A. Heerema, Weiqiang Zhao, Joseph M. Flynn, Jeffrey Jones, Leslie Andritsos, Kamal D. Puri, Brian J. Lannutti, Neill A. Giese, Xiaoli Zhang, Lai Wei, John C. Byrd, Amy J. Johnson

Blood (2010) 116 (12): 2078–2088.

https://doi.org/10.1182/blood-2010-02-271171

Published: 2010

Journal Articles

17-DMAG targets the nuclear factor-κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition

Erin Hertlein, Amy J. Wagner, Jeffrey Jones, Thomas S. Lin, Kami J. Maddocks, William H. Towns, III, Virginia M. Goettl, Xiaoli Zhang, David Jarjoura, Chelsey A. Raymond, Derek A. West, Carlo M. Croce, John C. Byrd, Amy J. Johnson

Blood (2010) 116 (1): 45–53.

https://doi.org/10.1182/blood-2010-01-263756

Published: 2010

Includes: Supplemental data

Journal Articles

17-DMAG Targets the NF-κB Family of Proteins to Induce Apoptosis in CLL: Clinical Implications of Hsp90 Inhibition

Amy J Wagner, Erin K Hertlein, PhD, Chelsey A Raymond, Derek A West, Joseph M Flynn, DO, MPH, Thomas Lin, MD, PhD, Amy J Johnson, PhD, John C Byrd, MD

Blood (2008) 112 (11): 381.

https://doi.org/10.1182/blood.V112.11.381.381

Published: 2008

Journal Articles

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Thomas S. Lin, MD, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD,MPH, Mollie E. Moran, CNP, Sarah Broering, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Larry J. Schaaf, PhD, Linda S. Mahoney, RN, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, John C. Byrd, MD

Blood (2007) 110 (11): 3104.

https://doi.org/10.1182/blood.V110.11.3104.3104

Published: 2007

Journal Articles

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Nyla A. Heerema, PhD, John C. Byrd, MD, Leslie A. Andritsos, MD, Gerard Lozanski, MD, Kristie Blum, MD, Beth Fischer, RN, Jeffrey A. Jones, MD, Mollie E. Moran, CNP, Sarah Groering, Larry J. Schaaf, Linda S. Mahoney, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch A. Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Thomas S. Lin, MD

Blood (2007) 110 (11): 3107.

https://doi.org/10.1182/blood.V110.11.3107.3107

Published: 2007

Journal Articles

Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells.

David M. Lucas, PhD, Syed-Rehan A. Hussain, PhD, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Jamie M. Allison, BA, Sara E. Guster, MS/MBA, Thomas S. Lin, MD, John C. Byrd, MD, Mark W. Julian, PhD, Elliott D. Crouser, MD, Michael R. Grever, MD

Blood (2006) 108 (11): 2098.

https://doi.org/10.1182/blood.V108.11.2098.2098

Published: 2006

Journal Articles

The Geldanamycin Derivative DMAG Demonstrates Improved Cytotoxicity and Down-Modulation of Hsp90 Client Proteins Relative to 17-AAG in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Clinical Trials in CLL.

Amy J. Johnson, PhD, Amy J. Wagner, BA, Lisa L. Smith, MS, David M. Lucas, PhD, Michael D. De Lay, BA, Jamie M. Allison, BA, S. Percy Ivy, MD, Thomas S. Lin, MD,PhD, John C. Byrd, MD

Blood (2006) 108 (11): 2101.

https://doi.org/10.1182/blood.V108.11.2101.2101

Published: 2006

NARROW

A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines

Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

17-DMAG targets the nuclear factor-κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition

17-DMAG Targets the NF-κB Family of Proteins to Induce Apoptosis in CLL: Clinical Implications of Hsp90 Inhibition

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells.

The Geldanamycin Derivative DMAG Demonstrates Improved Cytotoxicity and Down-Modulation of Hsp90 Client Proteins Relative to 17-AAG in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Clinical Trials in CLL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only